Core Viewpoint - The company, Zhixiang Jintai, has achieved a significant milestone with its drug, GR1802 injection, for the treatment of adult seasonal allergic rhinitis, successfully reaching the primary endpoint in Phase III clinical trials and has submitted a new drug application to the National Medical Products Administration (NMPA) [1] Group 1 - GR1802 injection is a fully humanized monoclonal antibody targeting IL-4Rα, designed to inhibit Th2-type inflammatory responses by blocking the binding of IL-4 and IL-13 to IL-4Rα [1] - The new drug application for GR1802 injection for moderate to severe atopic dermatitis in adults was accepted in September 2025, indicating ongoing development in this area [1] - Multiple indications for GR1802 injection are currently in clinical trial stages, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III, and asthma in Phase II [1] Group 2 - As of the announcement date, only two other drugs targeting the same pathway have been approved for marketing in China, highlighting the competitive landscape for GR1802 injection [2]

Group 1 - The core viewpoint of the news is that Zhixiang Jintai has made significant progress in new drug development, with multiple new drug applications accepted by the National Medical Products Administration (NMPA) [1][2] - The company participated in a performance briefing for the first half of 2025, where executives discussed operational results and financial status with investors [1] - Zhixiang Jintai's drug "Tairiqibai monoclonal antibody injection (GR1802)" has reached the primary endpoint in a Phase III clinical trial for moderate to severe atopic dermatitis and has submitted a new drug application [1][2] Group 2 - The company is an innovation-driven biopharmaceutical enterprise focused on the research, production, and commercialization of antibody drugs since its establishment in 2015 [2] - Zhixiang Jintai has 14 products under development and has established six core technology platforms to support continuous innovation [2] - The acceptance of multiple new drug applications and participation in industry performance briefings highlight the company's strength in innovative drug development and its proactive communication with investors [2]

Core Viewpoint - The company Zhixiang Jintai (688443.SH) has achieved the primary endpoint in the Phase III clinical trial of its drug Taliqibai Injection (GR1802) for the treatment of moderate to severe atopic dermatitis in adults, and has submitted a new drug application to the National Medical Products Administration (NMPA) which has been accepted [1] Group 1: Drug Development - Taliqibai Injection (GR1802) is a recombinant fully human anti-IL-4Rα monoclonal antibody developed by the company, targeting IL-4Rα [1] - The drug specifically binds to the human IL-4Rα on cell surfaces, blocking the binding of IL-4 and IL-13, thereby inhibiting downstream STAT6 phosphorylation and CD23 upregulation, which suppresses Th2-type inflammatory responses mediated by IL-4 or IL-13 [1] Group 2: Clinical Trials - Multiple indications for Taliqibai Injection are in clinical trial stages, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, both in Phase III trials [1] - Seasonal allergic rhinitis in adults and adolescents is also in Phase III trials, while asthma is in Phase II trials, and atopic dermatitis in children/adolescents is in Ib/IIa trials [1]

Core Viewpoint - Zhixiang Jintai (688443.SH) announced that its drug Talizhi Baikan (GR1802 injection) has achieved primary endpoint indicators in a Phase III clinical trial for moderate to severe atopic dermatitis in adults, and the company has submitted a new drug application to the National Medical Products Administration (NMPA) which has been accepted [1] Group 1 - Talizhi Baikan (GR1802 injection) is a fully humanized recombinant anti-IL-4Rα monoclonal antibody developed by the company, targeting IL-4Rα [1] - The drug specifically binds to human IL-4Rα on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4Rα, thereby inhibiting downstream STAT6 phosphorylation and CD23 upregulation, which suppresses Th2-type inflammatory responses mediated by IL-4 or IL-13 [1] Group 2 - Multiple indications for Talizhi Baikan are in clinical trial stages, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III trials, seasonal allergic rhinitis in both adults and adolescents in Phase III trials, asthma in Phase II trials, and atopic dermatitis in children/adolescents in Ib/IIa trials [1]